Erlotinib in non- or light-smoker patients with NSCLC harvoring wild type EGFR and wild type ALK

Erlotinib in non- or light-smoker patients with NSCLC harvoring wild type EGFR and wild type ALK - Erlotinib in light-smoking lung adenocarcinoma with wild EGFR and ALK

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000013055

Enrollment

Registered

2014-02-03

Start date

2014-02-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung adenocarcinoma

Interventions

Erlotinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Lung adnocarcinoma Negative in the 1st EGFR and ALK test At least one cytotixic chemotherapy No EGFR-TKI treatment Eligible for erlotinib PS0-2 Sufficient organ function

Exclusion criteria

Exclusion criteria: Concomitant interstitial pneumonotis Concomitant other advanced cancer Smoing index > 100

Design outcomes

Primary

Measure	Time frame
Response rate	—

Countries

Japan

Contacts

Public ContactF

Osaka Department of Thoracic Oncology

imamura-fu@mc.pref.osaka.jp0669721181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026